Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Passes User Fee Reauthorization With FDA/Industry Proposals Intact

This article was originally published in The Gray Sheet

Executive Summary

Legislation reauthorizing the medical device user fee program passed the Senate May 9. Action is now needed in the House to prevent the program from expiring on September 30
Advertisement

Related Content

Congress Approves FDA Reform/User Fee Bill In The Nick Of Time
FDA User Fee Reauthorization Bill Cleared For House Floor Action
Controversy Persists Over House Pre-emption Provision
Device User Fee Reauthorization Imperative By August, HHS Official Says
Corrections
Postmarket User Fees Floated At House Subcommittee Hearing
Chart: FDA Revitalization Act: Device-Related Provisions
MDUFMA Renewal Plan Spreads Fee Burden More Evenly; Senate Panel OKs
FDA Will Drop “Cycle” Goals, Prioritize Interactive Device Reviews
Rx Bill Concedes Devices Distinct From Drugs, Yet Carries Device Provision
Advertisement
UsernamePublicRestriction

Register

MT024802

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel